A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Clinical trial NCT07217171 · RECRUITING

Trial details

NCT number: NCT07217171
Sponsor: EvolveImmune United, Inc
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Bladder Cancer Squamous Cell Carcinoma of the Lung Esophageal Squamous Cell Carcinoma Tongue Squamous Cell Carcinoma Cutaneous Squamous Cell Cancer Penile Squamous Cell Carcinoma Anal Squamous Cell Carcinoma Vulvar Squamous Cell Carcinoma Cervical Squamous Cell Carcinoma Vaginal Squamous Cell Carcinoma Urethral Squamous Cell Carcinoma

Start date: 2025-11-13
Primary completion: 2029-01-29
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.